Clinical trials: COVID, Coronavirus
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Safety and Effectiveness of an Immunobiological Drug in CoViD-19
The aims of this study is to analyze the efficacy and safety of a passive immunotherapy strategy using hyperimmune equine serum known as Anti-SARS-CoV-2 elaborated by the National Institute for the Production of Biologicals…
- Conditions
- COVID-19 Pneumonia, COVID-19 Respiratory Infection, Covid19
- Trial name
- INPB001 (NCT04913779)
- Testing
- Anti-SARS-CoV-2
- Where
- Argentina
- Volunteers
- 200 people
- Sponsor
- Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran
COVID-19
Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19
This is a randomized, double-blinded, phase ⅠV clinical trial of SARS-CoV-2 inactivated vaccine manufactured by manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT05079217
- Testing
- High-dosage SARS-CoV-2 vaccine, Medium-dosage SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
COVID-19, Lung Infection
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
A phase 2/3 multi-center randomized, double-blind, parallel arm, placebo- controlled study in Adult Subjects Hospitalized with Severe SARS-CoV-2 Positive Pneumonia to determine the potential of opaganib to improve and/or…
- Trial name
- NCT04467840
- Testing
- Opaganib
- Where
- 57 sites in United States, Brazil and 8 more
- Volunteers
- 475 people
- Sponsor
- RedHill Biopharma Limited
SARS-CoV-2 Infection
COVID-19 Omicron BA.5 Subvariant Dose Finding Infection Study
A phase 1, dose-finding open label clinical infection, safety and viral detection optimization in healthy volunteers immunologically experienced against SARS-CoV-2.
- Trial name
- NCT06478420
- Testing
- Omicron BA.5 SARS-CoV-2 challenge virus
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Oxford
SARS-CoV-2, COVID-19
Clinical Evaluation of the VitaSIRO Solo™ Respiratory Assay
The purpose of this clinical trial is to demonstrate the clinical performance of the VitaSIRO solo™ SARS-CoV-2/Flu/RSV Assay in detecting SARS-CoV-2, Flu A, Flu B and RSV in symptomatic population.
- Conditions
- SARS-CoV-2, COVID-19, RSV, Influenza
- Trial name
- NCT06689423
- Testing
- Credo POCT Device
- Where
- Taiwan
- Volunteers
- 1,268 people
- Sponsor
- Credo Diagnostics Biomedical Pte. Ltd.
COVID-19 Pandemic
Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization
A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2…
- Trial name
- COVID-19 (NCT05125874)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Covid19, Ivermectin Poisoning
Adverse Effects of Ivermectin Used in Egypt During COVID-19
retrograde study of common and rare adverse effects of multiple doses of ivermectin used during the coivd 19 pandemic in egypt
- Conditions
- Covid19, Ivermectin Poisoning, Drug Toxicity, Drug Side Effect
- Trial name
- NCT04747678
- Testing
- Ivermectin
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Menoufia University
COVID-19
Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine
This was a randomized, two-armed, double-blind, placebo-controlled trial designed to evaluate the safety and immunogenicity of a booster dose of an adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine (SpikoGen)…
- Trial name
- NCT05175625
- Testing
- SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
- Where
- Iran
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Cinnagen
Covid-19
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19
This is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg BID on D1 and 400 mg/day on D2 to D7) and azithromycin (500 mg/ 5 days) to treat mild ambulatory COVID-19 patients.
- Trial name
- NCT04348474
- Testing
- Hydroxychloroquine Sulfate, Azithromycin Tablets
- Where
- Brazil
- Volunteers
- 200 people
- Sponsor
- Azidus Brasil
COVID-19, Sars-CoV-2 Infection
Efficacy, Immunogenicity, and Safety of TURKOVAC Vaccine Versus the CoronaVac Vaccine Against COVID-19 in Healthy Adolescent
This study is a multi-center, randomized, national, observer-blinded, active-controlled phase IIB clinical trial to determine the efficacy, immunogenicity, and safety of two-doses of inactive COVID-19 vaccine (TURKOVAC) vaccine…
- Trial name
- NCT05230940
- Testing
- TURKOVAC, CoronaVac
- Where
- 14 sites in Turkey (Türkiye)
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Health Institutes of Turkey
COVID-19, Sars-CoV2
Progesterone for the Treatment of COVID-19 in Hospitalized Men
The purpose of this study is to assess safety and efficacy of progesterone for treatment of COVID-19 in hospitalized men.
- Trial name
- NCT04365127
- Testing
- Progesterone 100 MG
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sara Ghandehari
Long COVID, Post-COVID Syndrome
Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
REGENECYTE (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.
- Conditions
- Long COVID, Post-COVID Syndrome, Post COVID-19 Condition
- Trial name
- NCT05682560
- Testing
- REGENECYTE
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- StemCyte, Inc.
COVID-19, SARS-CoV-2 Infection
COVID-19: SARS-CoV-2-CZ-PREVAL-II Study
The aim of the SARS-CoV-2-CZ-PREVAL-II Study is to quantify the prevalence of participants with antibodies against SARS-CoV-2 and/or cell immunity against SARS-CoV-2 in specific subjects cohorts.
- Trial name
- NCT05096962
- Testing
- Quantitative analysis of SARS-CoV-2 antibodies, Cellular immunity
- Where
- Czechia
- Volunteers
- 7,268 people, healthy volunteers welcome
- Sponsor
- Institute of Health Information and Statistics of the Czech Republic
Post-Acute COVID-19 Syndrome
REVERSE-Long COVID-19 With Baricitinib Study
REVERSE-LC is a phase 3 trial of baricitinib versus placebo in adults with neurocognitive impairment (a form of Alzheimer's Disease and Related Dementias or ADRD) or cardiopulmonary symptoms due to Long COVID.
- Trial name
- REVERSE-LC (NCT05858515)
- Testing
- Baricitinib 4 MG
- Where
- 6 sites in United States
- Sponsor
- Vanderbilt University Medical Center
Covid19, SARS-COV-2 Infection
A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2
To evaluate the prevention of SARS-COV-2 infection after administration of DWJ1248 in person who contact from COVID-19 confirmed patient compared to the placebo.
- Trial name
- NCT04721535
- Testing
- DWJ1248
- Where
- South Korea
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Covid19
Study of Codivir in Patients With COVID-19
This is an open-label study to evaluate the safety and preliminary efficacy of Codivir in 12 mild or moderate COVID-19 patients and onset of symptoms within 72h prior to their inclusion.
- Trial name
- Codivir (NCT04930861)
- Testing
- Covidir injections, One Step Test, IgM and IgG dosage
- Where
- Brazil
- Volunteers
- 12 people
- Sponsor
- Code Pharma
COVID-19
Markers of Severity (CD177,S100A8 &S100A12) in Sever Acute Respiratory Syndrome Coronavirus 2(SARS-COV-2) Patients
Patients infected with covid-19 have a series of clinical manifestations, including fever, cough, myalgia or fatigue, dyspnea, even acute respiratory distress syndrome (ARDS), acute cardiac injury and secondary infection, and a…
- Trial name
- NCT05201625
- Testing
- real time PCR
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Sohag University
COVID-19, SARS-CoV-2 Infection
A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects
Trial to evaluate the safety and immunogenicity of one or two boosting doses of Comirnaty or one dose of BNT162b2s01 (Variant of concern [VOC] strain B.1.351) in BNT162-01 trial participants, or two boosting doses of Comirnaty in…
- Trial name
- NCT04949490
- Testing
- BNT162b2s01, BNT162b2
- Where
- 4 sites in Germany
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Healthy
Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers
ZYIL1 is a novel oral selective NLRP3 inflammasome inhibitor which prevents NLRP3-induced ASC oligomerization, thus inhibiting NLRP3 inflammasome pathway.
- Trial name
- NCT04731324
- Testing
- ZYIL1 capsule
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
Infectious Disease
Effectiveness of Convalescent Plasma Therapy in 8 Non-Intubated COVID-19 Patients in Indonesia: A Case Series
This is the first Case Studies article highlight factors determine the effectiveness of Convalescent Plasma Therapy (CPT) in Indonesia, accompanied by supporting data and images before and after the patients received the therapy.
- Trial name
- NCT05046652
- Testing
- Convalescent Plasma Therapy
- Where
- Indonesia
- Volunteers
- 8 people
- Sponsor
- Maranatha Christian University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.